ALFA Finder| Execution period | 12 months |
|---|
NSE filing, NSE: MEDICAMEQ. Summary written from the filing by ALFA Finder's alert engine.
Medicamen Biotech Ltd: key numbers
- Share price
- ₹275.45
- Market cap
- ₹387.4 Cr
- Revenue (annual)
- ₹197.8 Cr
- Net profit (annual)
- ₹9.64 Cr
- P/E (TTM)
- 35.8×Sector 43.8×
- Promoter holding
- 42.57%+2.11% QoQ
- FII holding
- 4.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medicamen Biotech Ltd
All →Medicamen Biotech Board Meeting Date
Medicamen Biotech will meet on 13 Nov 2026 to consider half-yearly results for September 2026. Trading window stays closed from 01 Oct to 16 Nov 2026.
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 50 lakh equity shares at ₹530 per share under its preferential issue. The allotment raises ₹265 Crore in fresh equity capital.
- Value
- ₹265.0 Cr
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 5,00,000 equity shares at ₹530 each in a preferential issue to one investor. The allotment raised ₹26.5 Crore, taking paid-up capital to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Convertible Warrants
Medicamen Biotech allotted 5,00,000 equity shares to Shivalik Rasayan Ltd via warrant conversion at ₹530 each, raising ₹26.5 Crore. Paid-up capital rises to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended 30 September 2026.
Medicamen Biotech Other Announcement
Medicamen Biotech Limited's Director Sanjay Bansal sold 32,813 shares on the open market, as per a regulatory filing.
- Value
- ₹1.05 Cr
Other management change announcements
All →Edelweiss Financial Services Management Change
Promoter director Venkatachalam Ramaswamy resigned as Non-Executive Director and Vice Chairman effective November 11, 2026. He also sought reclassification from promoter to public category, pending approvals.
Abans Financial Services Management Change
Abans Financial Services' Chief Executive Officer Chintan Mehta resigned with immediate effect. Mayank Mundhra was appointed Whole-Time Director from November 11, 2026, subject to shareholder approval.
Ortin Global Management Change
Ortin Global's auditor M/s. Mathesh & Ramana resigned effective 12 Nov 2026, citing other professional commitments. S. D. Mehta and Co. was appointed as replacement.
Tierra Agrotech Management Change
Tierra Agrotech appointed Sridevi Dasari as Executive Director for 60 months, effective 16 November 2026. She is Group Company Secretary and Legal Head of CCL Products (India).
- Execution
- 60 months
National Peroxide Management Change
National Peroxide Limited appointed Mr. Amit Shah as General Manager – Sales & Marketing, effective 11 November 2026, as a senior management personnel change. The appointment was approved at a board meeting held the same day.
Naperol Investments Management Change
Naperol Investments appointed Mr. Vinay Divakar Jayade as Non-Executive Non-Independent Director and Ms. Jinal Shah as Company Secretary, both effective 11 November 2026. Board-approved appointments with no financial value disclosed.
- Execution
- 3 months (Mr. Jayade's term of appointment)